This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
All content for MedEdicus Podcasts is the property of MedEdicus and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
(CE Podcast) Curbing Demodex Blepharitis: Meet the Mitey Challenge
MedEdicus Podcasts
48 minutes
11 months ago
(CE Podcast) Curbing Demodex Blepharitis: Meet the Mitey Challenge
Activity Description and Purpose Demodex are ectoparasites that inhabit human hair follicles, including those on the face and eyelashes. Large infestations can cause Demodex blepharitis, a condition that has been associated with dry eye, meibomian gland dysfunction, and rosacea. Until recently, there were no US Food and Drug Administration–approved treatments for Demodex blepharitis, and off-label treatments were not reliably effective. This podcast covers the diagnosis and treatment of Demod...
MedEdicus Podcasts
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
